# Lonafarnib for Patients With Hutchinson-Gilford Progeria Syndrome or Progeroid Laminopathy

> **NCT03895528** · — · APPROVED_FOR_MARKETING · sponsor: **Eiger BioPharmaceuticals**

## Conditions studied

- Progeria
- HGPS

## Interventions

- **DRUG:** Lonafarnib

## Key facts

- **NCT ID:** NCT03895528
- **Lead sponsor:** Eiger BioPharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** APPROVED_FOR_MARKETING
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2021-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03895528

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03895528, "Lonafarnib for Patients With Hutchinson-Gilford Progeria Syndrome or Progeroid Laminopathy". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT03895528. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*